Announced Fri, 7 Aug, 2026 · 14:49 IST
Q1 FY27 results: Zero revenue, loss widens to Rs 33.62 lakh
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Price reactionminutes from the announcement price · days from the prior close
—Next day
—
prior close
₹143.90
announcement price
In-mkt
timing
Nifty Microcap 250market · in no size index; the smallest one is used-0.0%—
Computers - Software & Consulting peers, median of 66sector+0.1%—
Minutes after the announcementfrom the announcement price · no benchmark
Stock
5m
—
10m
—
15m
—
30m
+0.0
Sessions after the filingfrom the prior close
StockMarketvs marketSectorvs sector
Reaction day
—+0.0—+0.0—
Next day
—-0.0—+0.1—
2d
—-0.2—+0.0—
3d
—+0.2—-0.7—
4d
—+0.3—-0.2—
5d
—+0.4—-0.5—
1w
—+0.9—-3.8—
15d
—+1.6—-1.9—
1m
—+2.0—-4.5—
2m
—+0.6—-10.6—
3m
—————
UpDownMarket · Nifty Microcap 250Sector · Computers - Software & Consulting peers, median of 66Pending
Minute windows have no benchmark: there is no intraday index history to compare against.
AI summary
iSERA Lifesciences posted zero revenue from operations in Q1 FY27 ended June 2026, compared with Rs 116.18 lakh for full FY26. Expenses of Rs 33.62 lakh led to a net loss of Rs 33.62 lakh, versus Rs 3.52 lakh loss in Q1 FY26. EPS was negative Rs 1.60. Reserves stand negative at Rs 49.81 lakh. The company operates in IT/ITES. Auditor review report is clean.
Likely market impact
Zero revenue and widening losses raise concerns about business viability and the need for fresh capital or a turnaround plan.